ArticleScientific reports2025
The impact of anemia on the risk of malignant central airway restenosis in lung squamous cell carcinoma patients post interventional bronchoscopy: a retrospective analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Anemia is known to correlate with tumor progression, which can result in narrowing of the airways. Although therapeutic bronchoscopy effectively manages central airway stenosis, restenosis frequently occurs. This study aimed to examine the relationship between hemoglobin levels and the risk of malignant central airway (MCA) restenosis in patients with lung squamous cell carcinoma (LUSC) undergoing interventional bronchoscopy. Data were collected from 196 LUSC patients with MCA stenosis who underwent therapeutic bronchoscopy between April 2014 and November 2023 at a tertiary hospital. Rates of MCA restenosis at 30 and 60 days post-therapeutic bronchoscopy were assessed. Piecewise linear regression, Cox regression analyses, and survival analysis were used to evaluate the impact of hemoglobin levels on restenosis risk, adjusting for potential confounders. The 30-day and 60-day rates of MCA restenosis were 27.0% and 56.1%, respectively. Hemoglobin levels, categorized into four groups, showed a significant trend of increased restenosis risk with decreasing levels (P for trend < 0.01), particularly pronounced in patients with hemoglobin levels < 120 g/L. Compared to those with hemoglobin ≥ 120 g/L, adjusted hazard ratios (aHRs) for restenosis were elevated at both 30-day (aHR 2.21, 95% CI 1.17-4.16) and 60-day (aHR 1.85, 95% CI 1.20-2.86). Interaction analysis indicated higher restenosis risk trends among patients ≤ 60 years old and those who received stent implantation. Anemia is linked to a heightened risk of MCA restenosis in patients with LUSC after interventional bronchoscopy, especially noticeable among younger patients. Moreover, stent implantation did not mitigate the risk of MCA restenosis within 2 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.